A novel vaccine against vaginal Chlamydia trachomatis

描述（由申请方提供）：预防沙眼衣原体（Ct）感染是一项关键的未满足的医疗需求。开发有效的疫苗不仅可以降低与这些感染相关的发病率，包括盆腔炎（PID）、不孕症、慢性盆腔疼痛和异位妊娠，而且还可以减少包括艾滋病毒传播在内的附带风险。尽管经过几十年的努力，目前还没有疫苗可用。产生有用的疫苗的能力受到以下限制：1）缺乏有效的方法来递送将引发保护性肱骨和细胞介导的应答的抗原，和2）鉴定将保护个体免受引起性传播疾病（STD）的Ct菌株的特异性抗原序列。EpitoGenesis，Inc.开发的专有营养免疫增强递送系统（NIDS）。和Dean实验室进行的广泛的序列评估，以及关于Ct和HIV-1疫苗构建体的令人兴奋的初步数据，提供了一个独特的机会，通过使用与用于粘膜和全身接种的新型、安全和有效的NIDS一起配制的新型抗原构建体，最终获得可以防止Ct阴道传播的有效疫苗。此外，粘膜和全身接种途径的组合，缺乏与人类抗原的序列同源性，以及来自EpitoGenesis和Dean实验室的有希望的初步结果，保证了一种新的疫苗设计和疫苗接种方法，有望成功。

DESCRIPTION (provided by applicant): Preventing Chlamydia trachomatis (Ct) infections represent a critical unmet medical need. Development of an effective vaccine would not only reduce the morbidity associated with these infections, including pelvic inflammatory disease (PID), infertility, chronic pelvic pain and ectopic pregnancy, but could also reduce collateral riss including HIV transmission. Despite decades of efforts, no vaccine is currently available. The ability to generate a useful vaccine has been limited by 1) the lack of an effective method to deliver antigens that will elicit protective humeral and cell-mediated responses, and 2) the identification of specific antigenic sequences that would protect individuals from the Ct strains that cause sexually transmitted diseases (STD). The proprietary nutritive immune-enhancing delivery system (NIDS) developed by EpitoGenesis, Inc. and the broad-based sequence assessment performed by the Dean lab, in addition to the exciting preliminary data on an Ct and HIV-1 vaccine constructs, provide a unique opportunity to finally obtain an efficacious vaccine that can protect against vaginal transmission of Ct through the use of the novel antigenic constructs formulated with the novel, safe and effective NIDS for mucosal and systemic vaccinations. Furthermore, combinations of mucosal and systemic vaccination routes, lack of sequence homology to human antigens, and promising preliminary results from both EpitoGenesis and the Dean lab warrant a novel vaccine design and vaccination approach that hold promise of success.